Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12208
Title: Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial.
Authors: Gianatti, Emily J;Dupuis, Philippe;Hoermann, Rudolf;Strauss, Boyd J;Wentworth, John M;Zajac, Jeffrey D;Grossmann, Mathis
Affiliation: Department of Medicine Austin Health, University of Melbourne, Heidelberg, AustraliaDepartment of Endocrinology, Austin Health, Heidelberg, Australia.
Department of Medicine Austin Health, University of Melbourne, Heidelberg, Australia.
Department of Medicine, Southern Clinical School, Monash University, Clayton, Australia.
Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Department of Medicine Austin Health, University of Melbourne, Heidelberg, AustraliaDepartment of Endocrinology, Austin Health, Heidelberg, Australia mathisg@unimelb.edu.au.
Issue Date: 7-May-2014
Citation: Diabetes Care 2014; 37(8): 2098-107
Abstract: To determine whether testosterone therapy improves glucose metabolism in men with type 2 diabetes (T2D) and lowered testosterone.We conducted a randomized, double-blind, parallel, placebo-controlled trial in 88 men with T2D, aged 35-70 years with an HbA1c ≤8.5% (69 mmol/mol), and a total testosterone level, measured by immunoassay, of ≤12.0 nmol/L (346 ng/dL). Participants were randomly assigned to 40 weeks of intramuscular testosterone undecanoate (n = 45) or matching placebo (n = 43). All study subjects were included in the primary analysis. Seven men assigned to testosterone and six men receiving placebo did not complete the study. Main outcome measures were insulin resistance by homeostatic model assessment (HOMA-IR, primary outcome) and glycemic control by HbA1c (secondary outcome).Testosterone therapy did not improve insulin resistance (mean adjusted difference [MAD] for HOMA-IR compared with placebo -0.08 [95% CI -0.31 to 0.47; P = 0.23]) or glycemic control (MAD HbA1c 0.36% [0.0-0.7]; P = 0.05), despite a decrease in fat mass (MAD -2.38 kg [-3.10 to -1.66]; P < 0.001) and an increase in lean mass (MAD 2.08 kg [1.52-2.64]; P < 0.001). Testosterone therapy reduced subcutaneous (MAD -320 cm(3) [-477 to -163]; P < 0.001) but not visceral abdominal adipose tissue (MAD 140 cm(3) [-89 to 369]; P = 0.90).Testosterone therapy does not improve glucose metabolism or visceral adiposity in obese men with moderately controlled T2D and modest reductions in circulating testosterone levels typical for men with T2D.
Internal ID Number: 24804695
URI: http://ahro.austin.org.au/austinjspui/handle/1/12208
DOI: 10.2337/dc13-2845
URL: http://www.ncbi.nlm.nih.gov/pubmed/24804695
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.